Leo Pharma (United States)

Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial

Andrew Blauvelt, Richard G. Langley, J.‐P. Lacour et al. · Journal of the American Academy of Dermatology · 2022 · 75 citations · Full text

Life Sciences, Dermatology, Immunology +16

Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis

Joseph F. Merola, Daniel Butler, Thomas Mark et al. · JAMA Dermatology · 2023 · 23 citations · Full text

Medicine, Dermatology, Pharmacotherapy +16

Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States

Jashin J. Wu, Karen A. Veverka, Minyi Lu et al. · Journal of Dermatological Treatment · 2018 · 18 citations

Medicine, Dermatology, Pharmacotherapy +13

Patient-oriented measures for phase 3 studies of tralokinumab for the treatment of atopic dermatitis (ECZTRA 1, 2, and 3)

Eric L. Simpson, Andreas Wollenberg, Weily Soong et al. · Annals of Allergy Asthma & Immunology · 2022 · 16 citations · Full text

Life Sciences, Dermatology, Pharmacotherapy +15

PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis

Linda Stein Gold, Jes B. Hansen, Dharm S. Patel et al. · Journal of the American Academy of Dermatology · 2020 · 16 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13